Pegylated interferon-α2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: Results of a cohort study

Antiviral Therapy

Volumn 15, Issue 4, 2010, Pages 599-606

  Lang, Jean Philippe ^a   Melin, Pascal ^b   Ouzan, Denis ^c   Rotily, Michel ^d   Fontanges, Thierry ^e   Marcellin, Patrick ^f,g   Chousterman, Michel ^h   Cacoub, Patrice ^i,j  

^a Hospital of Erstein   (France)

^b Hospital of Saint Dizier   (France)

^c INSTITUT ARNAULT TZANCK   (France)

^d ClinSearch   (France)

^e General Hospital of Bourgoin   (France)

^f BEAUJON HOSPITAL   (France)

^g CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^h CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j Sorbonne Université   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SUICIDE ATTEMPT; TREATMENT OUTCOME; VIOLENCE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FRANCE; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77956832961     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1566     Document Type: Article

References (31)

1. Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 2006; 31:335-344.
2. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123:476-482.
3. Cividini A, Pistorio A, Regazzetti A, et al. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. J Hepatol 1997; 27:455-463.
4. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160:172-174.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
7. Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther 2005; 21:1007-1015.
8. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006; 13:678-682. (Pubitemid 44401196)
9. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577-1580.
10. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-1211.
11. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876.
12. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25:39-47. (Pubitemid 28093154)
13. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64:708-714.
14. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54:565-572.
15. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7:165-168.
16. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131-132.
17. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15:300-303. (Pubitemid 30190745)
18. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
19. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793-798.
20. Mistler LA, Brunette MF, Rosenberg SD, Vidaver RM, Luckoor R, Iber M. Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha. Int J Psychiatry Med 2006; 36:449-455. (Pubitemid 47105281)
21. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007; 102:2426-2433.
22. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in 'difficult-to-treat' psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46:991-998.
23. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
24. American Psychiatric Association. [Diagnostic and statistical manual of mental disorders. 4th ed. Text revision]. Paris: Masson 2003. French.
25. Leplège A, Cosse E, Pouchot J, Coste J, Perneger T. [Medical Outcome Study Short Form 36 item health survey. User manual and interpretation guide scores.] Paris: Editions Estem 2001. French.
26. Lang JP, Michel L, Melin P, et al. Management of psychiatric disorders and addictive behaviours in patients with viral hepatitis C in France. Gastroenterol Clin Biol 2009; 33:1-7.
27. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26 Suppl 1:2S-10S.
28. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. J Hepatol 1999; 30:956-961.
29. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36 Suppl 1:S3-S20.
30. Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26 Spec No 2:B303-B320.
31. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101:2254-2262.